Fig 1.
(A) Representative sections from the ventral prostate lobe of Dunning tumor-bearing and control rats stained to visualize CD68+ macrophages (brown, 200X magnifications, T; tumor). (B) Volume density of CD68+ macrophages in the tumor-adjacent prostate tissue (TINT) and in controls. a; significantly different than controls, b; large G tumors significantly different than small G tumors, and c; significantly different than corresponding tumor at day 7, P<0.05, n = 5–13. (C) Scatterplot of the volume density of CD68+ macrophages in the tumor-bearing organ plotted against tumor weight (correlation coefficients are given in the result text).
The density of macrophages increases with tumor size, but MatLyLu (X) tumors attracted more macrophages than AT-1 (Δ) and G (O). Correlation coefficients are given in results section.
Fig 2.
(A) Representative sections showing mainly non-malignant parts of ventral prostate lobe of Dunning tumor-bearing and histologically normal prostate tissue in control rats stained to visualize CD163+ macrophages (brown, 200X magnification, the tumor border (marked T) is seen in the periphery of the sections). (B) Volume density of CD163+ macrophages in the tumor-adjacent normal prostate tissue (TINT) and in controls.
a; significantly different than controls, b; significantly different than corresponding tumor at day 7, and c; significantly different than corresponding tumor at day 10, P<0.05, n = 5–13.
Fig 3.
Volume density of toluidine blue+ mast cells in the tumor-adjacent prostate tissue (TINT) and in controls, a; significantly different than controls, b; large G tumors significantly different than small G tumors, c; significantly different than corresponding tumor at day 7, and d; significantly different than corresponding tumor at day 10, P<0.05, n = 5–13.
Fig 4.
(A) Vascular density (factor VIII), B) endothelial proliferation (BrdU labeling index), and (C) mural vascular cell proliferation (BrdU labeling index) in the tumor-adjacent prostate tissue (TINT) and in controls, a; significantly different than controls, b; large G tumors significantly different than small G tumors, c; significantly different than corresponding tumor at day 7, and d; significantly different than corresponding tumor at day 10, P<0.05, n = 5–13. (D) Scatterplot of the BrdU-labeling index in mural vascular cells plotted against tumor size. MatLyLu tumors (X) were considerably more effective than the other tumor types (AT-1; Δ and G; O) in stimulating growth of larger blood vessels in the tumor-bearing organ. Correlation coefficients are given in results section. (E) Representative sections from the ventral prostate lobe of Dunning tumor-bearing and control rats stained to visualize BrdU-labeled cells (Brown, 200X magnifications, T; tumors). Detail (400X magnifications) of vascular (endothelial cell marked with arrow, mural vascular cell marked with arrowhead) BrdU labeling in a 10 day MatLyLu tumor. (F) Representative sections from the ventral prostate lobe of Dunning tumor-bearing and control rats injected with pimonidazole to label hypoxic tissue (brown, 100x magnification, T; tumor).
Table 1.
Tumor size and proliferation of different orthotopic Dunning rat prostate tumors.
Table 2.
Comparison between G and AT-1 tumors of similar small sizes.
Table 3.
Comparison between G and AT1- tumors of similar large sizes.
Table 4.
Comparison between AT-1 and MatLyLu tumors of similar sizes.
Table 5.
Summary of previously reported TINT factors in human prostate cancer patients that relate to patient outcome.